Evogene Ltd Stock Other OTC
Equities
IL0011050551
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
05-23 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
Sales 2024 * | 14.99M 20.5M | Sales 2025 * | 25.85M 35.36M | Capitalization | 32.15M 43.97M |
---|---|---|---|---|---|
Net income 2024 * | -22M -30.09M | Net income 2025 * | -19M -25.99M | EV / Sales 2024 * | 2.14 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.24 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Evogene Ltd
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |